
    
      The study is a double blind placebo controlled at two hospitals in Lafayette, Louisiana
      aiming to enroll 1700 participants with a 1:1 randomization. The HCQ dose in 400mg twice on
      day 1, then 200mg twice weekly. The primary outcome variable is development of symptomatic
      COVID-19 infection. The secondary objectives are number of days absent from work due to
      symptomatic COVID-19 infection and rate of severe disease due to COVID-19 (hypoxia in setting
      of >50% lung involvement on chest imaging, respiratory failure, shock or end-organ damage).
      The study will enroll participants for four weeks with and plan to treat with
      hydroxychloroquine versus placebo for a total of 12 weeks.
    
  